This page has been robot translated, sorry for typos if any. Original content here.

Attention! The information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Description of the medicine: Buserelin (Buserelin)

BUSERELIN (Buserelin).

Synonym: Suprefact, Suprefakt.

Synthetic analogue of gonadotropin releasing factor.

Available in the form of acetate (C 60 H 86 N 16 O 13 · C 2 H 4 O 2 ).

It binds (competitively) to the receptors of the cells of the anterior pituitary gland and blocks their gonadotropic function: it inhibits the release of luteinizing and follicle-stimulating hormones, which leads to the suppression of the synthesis of sex hormones in the ovaries and seminal vesicles.

It is used for endometriosis, uterine fibroids, infertility, as well as for hormone-dependent prostate gland packs.

Assign intranasally and subcutaneously.

With endometriosis, 0.3 mg is administered intranasally 3 times a day, starting on the 1st or 2nd day after the onset of menstruation; treatment duration up to 6 months.

In preparation for the induction of ovulation, 0.2-0.5 mg is administered subcutaneously once a day or 0.15-0.3 mg intranasally 4 times a day for 1-3 weeks (before chorionic gonadotropin is prescribed), starting with 1st or 21st day of the menstrual cycle.

In the treatment of infertility, in vitro fertilization is administered intranasally at 0.15 mg 4 times a day, starting from the middle of the luteal phase of the menstrual cycle (21-24th day of the cycle) until the day of administration of the ovulatory dose of chorionic gonadotropin.

For prostate cancer, 6.6 mg are administered subcutaneously (applicator contents) once every 2 months.

Possible side effects: dyspeptic symptoms, impotence, gynecomastia, allergic reactions, mental disorders (anxiety, insomnia, impaired memory and attention, depression), dizziness, increased blood pressure, dry mucous membranes and skin, impaired liver function, leukopenia, thrombocytopenia, impaired hearing.

The drug is contraindicated in pregnancy and lactation.

Method of release: 0.3% solution for injection in vials of 1; 3 and 5.5 ml; 0.2% aerosol for intranasal use in 8.5 and 17.5 ml vials; implant in the form of 2 dosed rods of 6.6 mg for subcutaneous administration.